z-logo
Premium
Cationic chitosan‐modified silica nanoparticles for oral delivery of protein vaccine
Author(s) -
Wu Xi,
Farooq Muhammad Asim,
Li Tiantian,
Geng Tianjiao,
Kutoka Perpeuta Takunda,
Wang Bo
Publication year - 2021
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.37198
Subject(s) - chitosan , materials science , mesoporous silica , bovine serum albumin , nanoparticle , chemical engineering , cationic polymerization , mesoporous material , fourier transform infrared spectroscopy , surface charge , nuclear chemistry , chromatography , nanotechnology , polymer chemistry , chemistry , organic chemistry , engineering , catalysis
Mesoporous silica nanoparticles coated with Chitosan are exploited here as a potential carrier for oral vaccine delivery. Bovine serum albumin (BSA) was used as a protein antigen model to reveal the carrier property. Chitosan‐coated BSA‐loaded silica NPs had particle size 345 ± 60 nm with a cationic surface charge of 18.28 ± 0.71 mV. The encapsulation efficiency, drug loading was 25.34 ± 0.76 and 20.21 ± 0.48%, respectively. Transmission electron microscopy investigation showed the spherical shape of NPs, also confirmed surface coating around modified nanoparticles (NPs), and nitrogen absorption/desorption isotherm confirmed mesostructured inside the NPs. Fourier transform infrared spectroscopy did not show any physiochemical interactions between excipients and formulations. The structural stability of antigen after release from NPs was confirmed by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis analysis, and chitosan‐coated silica NPs exhibited a slow‐release pattern. The results of in vivo experiments presented that chitosan‐mesoporous silica NPs could induce a robust immune response in mice, indicating that chitosan‐mesoporous silica NPs might be used as a promising carrier for oral vaccine delivery.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here